These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32344898)

  • 1. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.
    Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
    Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
    Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
    Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
    Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
    Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
    Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
    Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
    J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.
    Zhang RX; Zhou ZG; Lu SX; Lu ZH; Wan DS; Pan ZZ; Wu XJ; Chen G
    Sci Rep; 2017 Nov; 7(1):16043. PubMed ID: 29167471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
    Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
    J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
    Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
    Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
    Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
    Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 19. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
    Warfel NA; Sainz AG; Song JH; Kraft AS
    Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.